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1. Introduction 
High altitude pulmonary edema (HAPE) is a form of high altitude idiopathy that occurs in a 
minority of people upon either the first or subsequent exposure to high altitudes. It is 
triggered by a shortage of oxygen and certain other predisposing factors, all of which lead to 
a sudden increase in pulmonary arterial pressure, increase in lung blood volume, 
disturbance of pulmonary circulation, and leakage of fluid in microcirculation into the 
pulmonary interstitium and alveoli. The clinical symptoms of this condition include 
dyspnea and hacking cough. 
HAPE is a severe type of acute high altitude disease, typically occurring at altitudes above 
4,000 meters. However, cases have been reported at altitudes as low as 2,261 meters in 
Xining, China. HAPE is a rapid-onset condition that can progress and change quickly, 
especially during the first stage of high altitude exposure, usually within a week, peaking 
within three days. According to a report based on 332 cases, 63% of HAPE patients 
presented symptoms within three days, and the fastest onset was after only a few hours. 
HAPE occurs mostly in unacclimatized sea-level residents when they first ascend to high 
altitudes or acclimatized individuals ascending from lower to higher altitudes. It can also 
occur in long-term high altitude residents or high altitude natives undertaking excessive 
physical activities or in those who return to high altitudes after living in low-altitude areas 
for a period of time. HAPE patients can recover after short-term treatment and continue to 
stay at high altitudes. However, improper treatment may lead to negative effects. The 
incidence rate is closely related to the altitude, rapidity of exposure, season, the individual’s 
physical condition, and the intensity of activity. 
2. Epidemiology 
2.1 Incidence rate 
1. Population Incidence 
The incidence rate of HAPE varies significantly between China and the others country 
reports, for example it ranges between 0.15% and 9.9% in Chinese report. The incidence rate 
is higher in kids and teenagers than in adults. For instance, data collected from the Andes 
Mountain area of Peru reports that the incidence rate was 10% in children aged 2-12, 17% in 
teens aged 13-20, and 3% in adults over 21.  
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2. Hospitalization rate 
Due to the differences in location and population served, different treatment facilities have 
reported rather different hospitalization rate. The Menon hospital, at an altitude of 3,450 
meters, treated 101 HAPE patients over two years, accounting for 5-10% of all inpatients in 
the department of internal medicine; a hospital in Changdu (Tibetan), at an altitude of 3,200 
meters, treated 33 HAPE patients over 11 years, accounting for 0.37% of all inpatients in the 
internal medicine department and 6.28% of all inpatients with high altitude diseases; the 
General Hospital of the Tibet Military Region, at an altitude of 3,658 meters, treated 2,853 
HAPE patients from 1956 to 2005, accounting for 89.6% of all inpatients with high altitude 
diseases during the same time period. 
3. Age Distribution 
Reports from the Andes and Rocky Mountain areas show higher incidence in children, but 
occurrences in children below 2 years old are rare and the maximum age of all HAPE 
patients covered in these reports was found to be 53 years old. In the General Hospital of the 
Tibet Military Region, the youngest HAPE patient was 1 year old and the oldest one was 63 
years old. We think that HAPE can occur at any age, but children and young adults are 
more susceptible. 
4. Gender Differences 
HAPE can occur in both males and females. Many reports show higher incidence in males, 
mainly because more males travel to high altitude areas. In mountaineering and high altitude 
medical research teams, male participants are more common, hence a higher reported 
incidence of HAPE in males. Horrobin et al. mentioned that in Kenyan mountain areas there 
were many female mountaineers, none of whom developed HAPE. However Hultgren et al. 
reported that among 97 lifelong mountain residents, HAPE occurred mainly in females. 
5. Racial Differences 
It has been shown that there is no significant difference in HAPE incidence between 
Peruvian Indians and Caucasians in the plateau areas of Peru. However, some have 
suggested that the Sherpa of Nepal have a lower HAPE incidence than the Indians of Peru. 
They point out that the Indians have only inhabited the Andes for about 10,000 years, 
whereas the Sherpa, originally from the Tibetan Plateau, have lived in high altitude areas for 
several tens of thousands of years. Therefore, the Sherpa may be more adapted to high 
altitudes environment than Peruvian Indians. Our investigation found that, on the Tibetan 
Plateau, HAPE incidence in native Tibetans was lower than in Han immigrants. In the 923 
HAPE cases treated by the General Hospital of the Tibet Military Region over the past ten 
years, there was only one Tibetan patient. Recently we have retrospectively analyzed for 
severe acute mountain sickness of 3184 Inpatients cases in General Hospital of Tibet Military 
region Hospitalization from June 1956 to June 2005, and in which the incidence and clinical 
characteristics of native Tibetan plateau were analyzed.The results detected 24 cases of high 
altitude native Tibetan suffering severe cases of acute mountain sickness, high altitude 
pulmonary edema 21 cases and high altitude cerebral edema 3 cases in them, incidence of 
severe acute mountain sickness in native Tibetan population was 0.75% (24/3184). 
6. First and Repeated Exposure to High Altitudes 
Whether triggered by the patient’s first or a subsequent exposure to high altitude, HAPE onset 
usually takes place between one and seven days, but it can start as early as three hours or as 
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late as ten days after exposure. Occasionally, HAPE is triggered in high altitude residents by 
such factors as fatigue. For those who travel to high altitudes by plane, the typical time of 
HAPE onset is within three days. Data collected from Peru and the U.S. suggest that high 
altitude residents are likely to develop HAPE when returning to the plateau after spending 
typically one to three weeks on the plains. In Tibetan areas, HAPE tends to be triggered when 
residents spend typically three to six weeks on the plains before returning.  
7. Mode of Transportation to High Altitude Area 
Traveling to high altitude areas, whether on foot, by ground vehicle, or by airplane, can 
trigger HAPE. In recent years, as more people take airplane flights to the Tibetan Plateau, 
the number of HAPE patients who have arrived by plane has substantially increased. 
Among the 2,853 HAPE patients treated by the General Hospital of the Tibet Military 
Region between 1956 and 2005, 2,054 patients were traveled to Tibet by airplane. 
8. Occupation and Labor Intensity 
HAPE can occur in individuals of all occupations when they are exposed to high altitudes, 
but it is more common in those engaged in heavy physical labor. For instance, during the 
Qinghai-Tibet Highway, construction workers have a higher HAPE incidence than drivers, 
who in turn have a higher HAPE incidence than travelers taking rides. Those who are 
rapidly exposed to high altitudes and extreme fatigue are particularly susceptible to HAPE. 
Therefore, individuals engaged in physical activities at high altitudes, such as plateau 
mountaineering, alpine skiing, or traveling to high altitudes are all at risk for HAPE. In 
addition, HAPE is more likely to occur in young boys, as they tend to be more active and 
less willing to rest than young girls and adults.  
9. Season of Onset and Changes in Climate  
HAPE can occur in any season, but in general it is more common in the winter and spring. 
Earlier statistics from domestic show the onset of HAPE to be distributed mostly from 
November to March of the next year. More recent data suggest an increase in the prevalence 
of HAPE between January and October, mainly because there have been more people 
traveling to and from the plateau or engaging in high altitude activities during this period.  
10. Upper Respiratory Tract Infection and Acute mild mountain sickness 
Upper respiratory tract infection can also trigger HAPE. Among the 865 HAPE patients 
treated by a Tibetan hospital in Lhasa, 30% had already had a previous upper respiratory 
tract infection at the time of onset. It is suggested that upper respiratory tract infection may 
trigger HAPE because contracting an upper respiratory tract infection after reaching a high 
altitude substantially worsens the shortage of oxygen. 
A minority of those who show Acute mild mountain sickness (AMMS) may develop HAPE 
without prompt treatment. Among the 230 HAPE cases reported by a hospital in southern 
Xinjiang, 112 (47%) started out with AMMS. From this it can be concluded that, when 
developing acute or even minor AMMS or upper respiratory tract infection, one should rest 
and receive immediate treatment to prevent the condition from progressing to HAPE.  
11. Individual and Familial Susceptibility 
It has been reported that there are patients who develop severe HAPE more than two times, 
up to four times. Analysis on the 923 HAPE cases treated by a hospital in Lhasa showed that 
27% of the patients returning to high altitudes developed HAPE two or more times, two of 
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them even seven times. In our clinical experience we have seen one worker developing 
HAPE eight times. It is worth pointing out that some HAPE patients, when returning to 
high altitudes from the plain, may still develop HAPE again even if they take active 
measures to prevent it, such as bed rest, oxygen inhalation, and medicine. 
Some reports have shown that HAPE can co-occur in fathers and sons, brothers, and 
mothers and daughters. In Tibetan, Zhang reported HAPE occurring in three generations of 
one family, suggesting that familial and individual factors are involved in patients’ 
susceptibility to HAPE. Animal studies have also shown species and individual differences 
in susceptibility to HAPE. 
2.2 Fatality rate and cause of death 
1. Fatality Rate 
A collection of data showed that among 160 HAPE cases that occurred between 1958 and 
1965 in China, the fatality rate was 9.4%. In recent years, due to substantial improvements in 
medical conditions and the promptness of treatment, the fatality rate has decreased 
significantly. For instance, among the 923 cases of HAPE treated by the General Hospital of 
the Tibet Military Region in the northern Tibetan plateau, the fatality rate was 0.33%.  
2. Cause of Deaths 
When treated promptly, most HAPE patients can recover in three to five days. However, 
death still occurs occasionally, and the causes can be generally summarized as belonging to 
one of the following categories: 1) Delay in diagnosis or treatment due to poor 
transportation and substandard medical conditions in remote areas. 2) Deterioration of the 
patient’s general condition caused by undiagnosed and untreated  complications such as 
heart failure, shock, massive pulmonary embolism, severe lung infection, and cerebral 
encephaledema/encephalorrhagia. 3) Severe HAPE may cause instant death, and co-
occurring pulmonary embolisms or encephalorrhagia can also lead to death.  
In summary, the incidence of HAPE is closely related to factors such as the mode of 
transportation to high altitude regions, the rapidity of exposure to high altitudes, the 
altitude itself, the medical support received, and individual susceptibility. Fatigue, upper 
respiratory tract infection, and excessive mental stress are all important triggers of HAPE.  
HAPE mostly occurs at altitudes above 3,000 meters because there are more immigrants at 
these altitudes. HAPE is not clearly correlated with age or gender. With the increasing of 
knowledge on HAPE and improvements to medical conditions, the fatality rate of HAPE 
has become extremely low. 
3. Causes and predisposing factors 
HAPE is a disease that occurs at high altitudes, its main cause being scarcity of oxygen. All 
factors that aggravate oxygen shortage in the body lower the body’s tolerance to low oxygen 
levels, or add load to pulmonary circulation can trigger HAPE. The most common 
predisposing factors include cold, fatigue, and upper respiratory tract infection. 
1. Cold 
Cold is a basic feature of plateau weather. The temperature on the Tibetan Plateau is on 
average more than 20°C lower than the temperature at sea level on the same latitude. At 
night, wind blows downwards from the snow-covered mountaintops, further accelerating 
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the drop in body surface temperature and making the night at high altitudes especially cold. 
Under external conditions, extreme coldness accompanied by wind and snow, the body will 
speed up its metabolism and consume more oxygen. At the same time, sympathetic 
excitability will become elevated, increasing the venous blood return from the peripheral 
veins, especially those on the surface of the skin, increasing the load of pulmonary 
circulation. In addition, pulmonary arterioles contract, inducing or aggravating pulmonary 
hypertension and eventually triggering HAPE.  
2. Fatigue 
Physical labor can increase oxygen demand ten times. Physical labor further aggravates 
oxygen shortage. In addition, physical labor at high altitudes increases the release of 
catecholamine, and hyperventilation can cause respiratory alkalosis, decrease the 
concentration of PaCO2, and lead to venoconstriction in the systemic circulation and 
subsequent increases both in the cardiac output of the right side of the heart and in 
pulmonary blood volume. Physical labor may further increase the pulmonary arterial 
pressure and decrease the concentration of PaCO2. Those who engage in excessive mental 
labor may also be susceptible to HAPE due to bodily fatigue. 
3. Upper respiratory tract infection 
Upper respiratory tract infection often causes fever, which increases oxygen consumption. If 
complicated by bronchitis, causing coughing and an increase in bronchial secretions, it will 
affect pulmonary ventilation and cause damage to the alveolar epithelia, impeding the 
generation of surface-active substances. According to statistics from Lhasa, 30% of HAPE 
cases were triggered by upper respiratory tract infections; data from southern Xinjiang 
showed 29%.  
4. Excessive mental stress 
Mental stress, anxiety, and fear can increase the release of catecholamine, which in turn 
increases pulmonary arterial pressure and triggers HAPE. 
5. Rapidity of exposure to high altitudes 
Among those who quickly enter the plateau areas by ground vehicle or by plane without 
adaptation trainings, the incidence of HAPE is substantially higher than in those who come 
by slower means. This is because rapid exposure to high altitudes leads to acute oxygen 
shortage, in which the body does not have enough time to adapt and shows extremely poor 
tolerance to low oxygen levels. 
6. Sleep and hypnotic drugs 
During sleep, the horizontal position of the body increases pulmonary blood volume (500 
ml more than an upright position). The shallow breathing that takes place during sleep, 
especially the periodic or irregular breathing accompanied by temporary apnea can 
aggravate the oxygen shortage.  
The incidence of HAPE mainly depends on the altitude, temperature, and adaptability of the 
body. High altitudes, low temperatures, and failure to acclimate are three basic factors that 
trigger HAPE. Individuals may not develop HAPE when only one factor is present. With 
two factors, the incidence rate is still not high. However, when all three factors are present, 
one is much more likely to develop HAPE. The incidence rate will increase further if there 
are other coexisting conditions. Those who are exposed to high altitudes without a thorough 
www.intechopen.com
 
Lung Diseases – Selected State of the Art Reviews 
 
544 
physical examination may have undetected organic cardiovascular diseases, organic 
diseases of the respiratory tract, liver, brain or kidney, malnutrition, or hypoproteinemia.  
4. Pathogenesis 
The incidence of HAPE is closely correlated with oxygen shortage at high altitudes. 
Currently, it is believed that the following processes are important: an excessive increase in 
the pulmonary arterial pressure, an increase in the permeability of the pulmonary 
capillaries, and impairment in alveolar epithelium water clearance. Among these three, an 
excessive increase in the pulmonary arterial pressure is the key link. 
4.1 Excessive increase in the pulmonary arterial pressure 
In 1904, Plumier et al. observed that low oxygen levels could lead to pulmonary 
hypertension. In 1964, Hultgnen performed right cardiac catheterization on four acute 
HAPE patients and found that in both the clinical and the recovery periods their pulmonary 
arterial pressures were significantly higher than that of control subjects at the same altitude, 
but their right arterial pressures, pulmonary venous pressures, and pulmonary capillary 
pressures were all essentially normal. There are several ways in which hypoxia that occurs 
at high altitudes can lead to pulmonary hypertension. 
1. Pulmonary vasoconstriction caused by hypoxia 
Hypoxic pulmonary vasoconstriction can redirect blood flow from low-oxygen alveolar 
regions to alveoli with higher oxygen content, which improves the ventilation/perfusion 
ratio and gaseous exchange, allows sufficient oxygenation of the blood, and increases 
arterial partial pressure of oxygen. However, pulmonary hypertension over a long period of 
time can also cause a series of pathophysiological changes and become an important 
pathologic basis of the initiation and development of HAPE. 
Studies on the mechanisms of hypoxic pulmonary vasoconstriction have demonstrated that, 
at low oxygen levels, the calcium concentration and transmembrane inflow of calcium ions 
in the pulmonary arterial smooth muscle cells are both significantly increased. As hypoxia 
the distribution of ions across the membranes of the pulmonary arterial smooth muscle cells, 
calcium and sodium ions flow into the cells and potassium ions flow out, causing the resting 
membrane potential to decrease, approaching its excitation threshold. This depolarization of 
the pulmonary arterial smooth muscle cells leads to increased reactivity of the pulmonary 
vessels and increased tension in the pulmonary arterioles and pulmonary arteriolar 
contraction. Some investigators believe that hypoxia directly changes the transmembrane 
potential of the pulmonary artery smooth muscle cells, leading to calcium ion inflow and 
decrease of excitation threshold of these cells, which then causes the smooth muscles of the 
arterioles to contract. In addition, vasoactive substances such as prostaglandin, 
thromboxane A2, angiotonin, and histamine may serve as regulators or synergists in hypoxic 
pulmonary vasoconstriction. However, persistent pulmonary hypertension caused by 
hypoxia may involve many vasoactive substances, the importance of each varying 
depending on the specific conditions. 
Hypoxic pulmonary vasoconstriction doubtlessly leads to pulmonary hypertension. As to 
how the pulmonary hypertension causes HAPE, currently there are three hypotheses. 
a. Regional maldistribution of blood flow. It has been proposed that when those who are 
sensitive to hypoxia at high altitudes are exposed to low-oxygen environments, their 
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muscle arterioles contract rigorously and precapillary resistance increases, while their 
non-muscle arterioles expand under pulmonary hypertension. The sudden increase in 
the hydrostatic pressure in the afflicted areas, plus other factors, can cause HAPE. As 
the changes described above occur in some but not all pulmonary arterioles and 
capillaries, the pathological changes manifested in the HAPE are usually regional, in 
accordance with the patchy distributions of edema in HAPE observed via X-ray. 
b. At high altitudes, as hypoxia leads to sudden increases in pulmonary arterial pressure, 
this high pressure in turn causes closed capillaries to instantly open. The abrupt 
increase in the capillary pressure then causes fluid to leak out.  
c. It has been proposed that fluid does not leak out through the capillaries but rather 
directly through the walls of pulmonary arterioles under the pulmonary hypertension 
caused by hypoxia. 
2. Increases in the resistance to pulmonary venous return 
The left ventricle is a relatively large, muscular organ that needs to overcome the high 
pressure and high resistance of systemic circulation to pump blood. At high altitudes, when 
oxygen shortage is minor, the body can employ a series of adaptive mechanisms on levels 
ranging from the systemic to the cellular to alleviate the damage to myocardia caused by 
hypoxia. However, when oxygen shortage is severe (such as may occur in cases of rapid 
ascent, excessive physical activity, and severe cold), there is no time for the body to set up 
these adaptive mechanisms of antihypoxia on the cellular level. In this case, hypoxia will 
cause direct damage to myocardia, especially those on the left side of the heart. Although 
left heart failure is not the main cause of HAPE, in clinical situations, cardiac agents have 
proven to be effective to a certain extent. Animal studies have also shown that compensation 
in heart function can significantly affect the progress of hypoxic pulmonary hypertension.  
When the myocardial damage induced by oxygen shortage exceeds a certain degree, the 
function of the left heart decompensates, causing an increase in the left ventricular end 
diastolic pressure (LVEDP) and in the left atrial pressure (LAP). This in turn boosts 
pulmonary hypertension and contributes further to the development of pulmonary edema. 
Pulmonary edema impedes gaseous exchange and oxygenation, and the resulting decrease 
in arterial partial pressure of oxygen further aggravates myocardial anoxia and damage. 
Increases in high altitude pulmonary blood volume cause an increase in the pulmonary 
venous resistance. 
3. Increases in pulmonary circulation blood volume 
Increases in pulmonary blood volume are another important factor that can elevate pressure 
in pulmonary circulation. It has been shown that 48-72 hours after healthy soldiers were 
airlifted from sea level to 3,658 meters, their pulmonary blood volumes increased by 82%. 
This is because oxygen shortage acts on the central nervous system and causes increased 
sympathetic excitability. Increased sympathetic excitability results in the large-scale release 
of catecholamines. At the same time, due to the increase in resistance in the peripheral 
vessels, the left ventricular load increases and cardiac output decreases while left atrial 
pressure increases. Pulmonary venous return is impeded, causing blood to fill the blood 
vessels of the lungs. The increased blood supply and reduced blood output in the 
pulmonary circulation increase pulmonary blood volume. The compensatory erythrocytosis 
and increase in both water and sodium retention caused by hypoxia increase blood volume 
in general, including pulmonary blood volume, which also leads to pulmonary edema.  
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4. Formation of micro-thrombi in the pulmonary vessels 
The formation of micro-thrombi in the pulmonary circulation is a pathological feature of 
HAPE. Autopsies of HAPE patients have found extensive blockages by thrombi in the 
pulmonary capillaries and some in the branches of the pulmonary veins and arteries, 
demonstrating that the formation of thrombi in the pulmonary vessels is relatively 
important to the pathogenesis of HAPE. Due to extensive micro-thrombus formation in the 
pulmonary capillaries and in other organs such as the brain, the liver, the spleen, the kidney, 
and the intestine, it has been suggested that hypoxic pulmonary hypertension results from 
abnormal coagulation and general thrombus blockage of the pulmonary capillaries.  
As to the mechanism by which micro-thrombi form in the pulmonary vessels, it is generally 
believed that as the levels of fibrinogen and anti-fibrinoclase released by the liver increase 
and levels of fibrinoclase activators released by the lung decrease, the resulting abnormal 
fibrinolysis is an important pathophysiological basis of the formation of micro-thrombi in 
the pulmonary vessels. Singh et al. proposed that hypoxia could lead to damage to the 
fibrinoclase system and that this damage might disturb the dynamic balance between the 
formation and dissolution of fibrin, causing fibrin to build up in the pulmonary vessels and 
hence cause the formation of micro-thrombi.  
Studies have shown that during the initial stages of HAPE, there are substantial increases in 
the level of platelet factor 3, and in the release of ADP, resulting in decreased platelet 
mobility. They have also found that, in HAPE patients, the levels of plasma 
immunoglobulins, including IgG, IgA, and IgM, all increase significantly. IgG and IgM can 
adhere to the surface of platelets and change their electrophoretic mobility, increasing 
platelet adhesivity and release of ADP. ADP can promote the utilizing of platelet factor 3, 
which further speeds up the coagulation process. Imbalances in cellular immune function 
cause immune complexes to build up. As the immune complexes activate blood coagulation 
factors, they further aggravate blood clotting in the blood vessels. The aforementioned 
weakening of the cellular immune function co-occurs with a decrease in the dissolution 
activity of fibrin. When the dissolution activity of fibrin improves, cellular immune function 
also recovers. In addition, recent studies have found that the magnesium content of 
erythrocytes and leukocytes increases significantly in healthy individuals who adapt well to 
high altitudes, but in HAPE patients it decreases significantly. Magnesium can alleviate 
coagulation by expanding blood vessels, stabilizing fibrinogen and platelets, and 
accelerating the dissolution of fibrin.  
4.2 Increases in the permeability of the pulmonary capillaries 
It has been reported that when dogs were placed at a simulated altitude of 6,401 meters, the 
flow of lymph in the right lymphatic duct increased. After inhaling pure oxygen, lymph 
flow decreased, the lymphatic duct expanded, but there was no sign of blockage. The causes 
of lymph flow increase included increased pressure and increased permeability resulting 
from pores opening in the walls of the lymphatic ducts in a low-pressure, low-oxygen 
environment. When the dogs’ arterial oxygen saturation dropped to 75% (corresponding to 
an altitude of 5,200 meters), the lymph flow began to increase. When the arterial oxygen 
saturation dropped to 52.5% (corresponding to an altitude of 6,100 meters), the lymph flow 
increased substantially. Once red blood cells enter the lymph, the capillaries are considered 
damaged. Schoene collected bronchoalveolar lavage fluid from HAPE patients in a lab at an 
altitude of 4,400 meters by branchofiberoscope. Component analysis showed elevated 
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protein content, even higher than that in the edema fluid collected from adult respiratory 
distress syndrome (ARDS) patients. All these directly demonstrate that HAPE results from 
the leakage of fluid, protein, and even blood formed elements caused by the increased 
permeability of the pulmonary capillaries, suggesting that HAPE is a type of protein-rich, 
high-permeability pulmonary edema. In 1991, West JB et al. successfully simulated the 
pathophysiological process of HAPE in the laboratory by increasing the pulmonary arterial 
pressure of laboratory animals. He observed that when the rabbits’ pulmonary capillary 
pressure reached 40 mmHg, the endothelia of the pulmonary capillaries and alveoli and 
sometimes even all the linings of the alveoli started to rupture.  
The mechanisms by which the pulmonary capillary permeability increases may include the 
following factors. 
1. Direct damage to the respiratory membrane structure 
According to studies, under emergency conditions involving hypoxia, the endochylema of 
the pulmonary capillary and alveolar endothelial cells become condensed, causing the cells 
to shrink, which in turn expands the intercellular space of the alveolar capillary membranes 
and increases their permeability.  
2. Decrease in secretion of alveolar surfactants 
The alveolar surfactant is a type of phospholipin secreted by alveolar epithelial type II cells. 
When the lung tissues experience shortages of oxygen and blood, the normal metabolism of 
the alveolar epithelial type II cells is disturbed, and the secretion of this substance decreases. 
In high altitude, secretion of this substance may decrease, causing the permeability of the 
barrier between the capillaries and lung tissues to increase, leading to HAPE.  
3. Increases in levels of acidic metabolites in local tissues 
The anaerobic metabolism increases and the acidic metabolites accumulate, causing the 
physicochemical properties of the adhesion substance between the capillary endothelial cells 
to change and the basilar membrane to denature, which eventually leads to increased 
capillary permeability. 
4. Respiratory tract infection 
Any respiratory tract infection can directly damage the pulmonary capillaries and tissues 
through inflammatory metabolites and bacterial toxins, increasing their permeability. It is 
already known that hypoxia can induce inflammatory reactions involving immunocytes and 
epithelial cells, and therefore it can be deduced that high altitude hypoxia may induce the 
secretion of inflammatory cytokines, causing HAPE by producing pulmonary extravasation. 
To understand the relationship between inflammation and the pathogenesis of HAPE, 
researchers measured the levels of several inflammation mediators under hypoxia, 
including interleukin-6 (IL-6), interleukin -1 receptor antibody (IL-1ra), and C reactive 
protein (CRP). The moderate increase of these inflammatory markers reflects the presence of 
general local inflammation and suggests that inflammation may be involved in the 
pathogenesis of HAPE. Another study measured continuously the level of NO, a marker of 
respiratory inflammation, in the expiratory air of human subjects, and found that at 4,359 
meters, the 13 subjects who were also HAPE patients among 28 subjects did not show trend 
of elevated NO levels during the clinical period, found the NO content in the expiratory air 
of subjects during their stay at high altitudes was 30% lower, indicating that respiratory 
tract infection does not precede HAPE. 
5.   Increases in plasma fibrinogen and the decreases in the dissolution activity of fibrin 
cause fibrin to accumulate in the pulmonary capillaries, forming thrombi that block them. 
This increases the permeability of the capillary walls. 
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4.3 Impairment of water clearance by the alveolar epithelium 
HAPE results from unbalanced fluid secretion and reabsorption in the alveoli. In particular, 
the amiloride-sensitive epithelial sodium channel (ENaC) is involved in 40-60% of the re-
absorption processes. It has also been found that 2 antagonist, which activates epithelial 
sodium channels (ENaC), also promotes water clearance in the lungs. In addition, in vitro 
studies have found that hypoxia inhibits Na+/K+-ATPase activity in alveolar epithelial type 
II cells as well as the co-transportation of Na, K, and Cl. This all suggests that hypoxia 
impedes the transmembrane re-absorption of water and sodium in epithelial cells. 
4.4 Increases in sympathetic excitability 
Studies have found that sympathectomy or blockage of cervical sympathetic nerves can 
eliminate HAPE. This suggests that the pathogenesis of HAPE is clearly related to 
sympathetic excitability. It has been found that the subjects’ sympathetic excitability 
instantly increased at 3,500 meters, reaching a peak value within 24-72 hours, which is 
exactly the period of time during which HAPE is most likely to occur.  
4.5 Individual susceptibility 
Given the same conditions, the incidence of HAPE shows differences along racial, individual, 
and age lines. A study reported that among the 43 patients with recurrent HAPE, thirty-two 
developed HAPE 2 times, seven 3 times, three 4 times, and one 6 times. This shows that 
individual susceptibility is one of the factors for the incidence of HAPE. When comparing 
HAPE patients to normal subjects, researchers have found that the chest circumferences and 
chest anteroposterior diameters of acute HAPE patients are both longer than those of controls. 
In addition, there are more circular muscle fibers on the pulmonary arteriolar walls of the 
acute HAPE patients. Individual differences in internal factors such as the tissue structure of 
the pulmonary vessels and immune function status may lead to individual differences in 
sensitivity, tolerance to hypoxia, and other steps of the pathogenesis of HAPE. 
In summary, the pathogenesis of HAPE is complex, involving many steps. Currently well-
accepted factors include the following: 
a. Hypoxia directly damages pulmonary capillary endothelial cells and expands or 
destroys the intercellular space, leading to general damage to the structure of the air-
blood barrier, which causes blood plasma to leak directly into the alveolar space. 
b. Hypoxia damages alveolar epithelial type II cells, diminishing their ability to secrete 
surfactants, leading to a decrease in alveolar surface tension, which causes the fluid and 
proteins in the pulmonary capillaries likely to leak out. 
c. Hypoxia prompts the alveoli to release cytokines such as histamine, serotonin, 
interleukin-1, interleukin-6, leukotriene E4, tumor necrosis factor, and C-reactive 
protein, causing capillary permeability to increase. 
d. Hypoxia prompts pulmonary arteriole constriction and an increase in vascular 
resistance, resulting in pulmonary hypertension. At the same time, sympathetic 
excitability increases and blood is redistributed, leading to an increase in pulmonary 
blood volume and body fluid retention, which causes capillary hydrostatic pressure to 
increase and fluid components to leak out, further aggravating HAPE. 
5. Pathological changes 
The pathological changes involved in HAPE mainly occur in the lungs. Visual inspections 
reveal increases in the volume, weight, and surface moisture of the two lungs and that the 
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peripulmonary membrane has become stretched, rubbery, and dark red in color. When 
pressed, pink spumous fluid streams to the surface. Under optical microscope, expansion of 
the pulmonary capillaries is observed, with red blood cells accumulating inside and 
bleeding around the vessels. The middle layers of the muscular pulmonary arterioles 
thicken, the elastic layers appear serrated, and the arterioles muscularize. The pulmonary 
arterioles are expanded and interrupted and capillary thrombi are formed. The bronchioles 
and alveoli present hyaline membranous edema, and the alveolar ducts become filled with 
blended protein fluid or cluttered red blood cells. The capillaries in the alveolar septum 
expand, with blood accumulating inside and forming thrombi. Under electron microscope, 
unformed edema fluid with low electron concentration is observed inside the pulmonary 
alveolar space. Red blood cells accumulate, the capillaries in the alveolar septum expand, 
the intercellular space between endothelial cells enlarges, and the endothelial cells swell. 
The number of pinocytotic vesicles and some vacuolated were increased. The alveolar 
epithelial type I and type II cells swell, shedding surface microvilli. The perinuclear space of 
the alveolar epithelial type II cells expands, and the laminated bodies in their cytoplasts 
increase in number and show vacuolization. 
6. Clinical manifestation 
Like those of other types of acute pulmonary edema, the clinical manifestation of HAPE 
includes dyspnea, cyanopathy, cough, the production of large amounts of white or pink 
spumous phlegm when coughing, and moist rales in one or both lungs. 
6.1 Symptoms 
At the early stage, the most common symptoms of HAPE include severe headache, dyspnea, 
palpitations, shortness of breath, chest tightness, chest pain, panic, extreme fatigue, 
weakness, persistent dry cough, worsened nighttime insomnia, pale complexion, and moist, 
cold skin. As the condition progresses, the above symptoms worsen, and patients may 
experience severe dyspnea, an inability to lie flat, and coughing out spumous phlegm, 
which is initially white or faint yellow in color and later turns pink, in some worse cases 
gushing out of the mouth and nose. Most patients display dysphoria while a minority 
experience hypersomnia, in some cases accompanied by altitude coma. 
6.2 Signs 
One distinctive sign of HAPE is moist pulmonary rales. In severe cases, moist rales can be 
heard in all regions of both lungs along with wheezing and phlegm. The cardiac sound is 
often masked. In mild cases, moist rales can be heard at the base of one or both lungs. Most 
patients display cyanosis in the lips, nail beds, and parts of the face. Due to dyspnea, 
patients often take bed rest in a semi-reclining position. About two thirds of patients 
experience fever, usually at 37.5-39oC. If body temperature persists over 38.5oC, it usually 
indicates complicating upper respiratory tract infection. Signs also include increased heart 
rate, loud or splitting P2, and grade 2-3 systolic murmur in the apex region of the heart. 
Some patients exhibit sulcus terminalis cordis expansion, possibly with diastolic gallop, 
jugular vein distention, hepatosplenomegaly, and edema complicated in some cases by 
cardiac insufficiency. Compared to other acute pulmonary edemas, HAPE has the following 
distinctive clinical features: 
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a. At early stages, HAPE patients only show symptoms of mild AMS, such as headache, 
dizziness, palpitations, insomnia, anorexia, and nausea. As these can be early 
symptoms of HAPE, they must be addressed with caution. Pulmonary auscultation 
may show normal results, but X-ray examination will reveal typical infiltrated shadows. 
b. In some patients, HAPE progresses very rapidly, with acute onset and severe 
symptoms. Patients experience extreme dyspnea, asphyxia, and rales in all lung 
regions, quickly reaching impending death status. They may exhibit bloody pleural 
fluid in one or both lungs before death. 
c. Patients tend to have high blood pressure, fine pulse, tachycardia, loud or splitting P2, 
and either a mild systolic murmur or diastolic gallop in the apex region of the heart. 
Only a few also experience right heart failure. 
d. Some patients mainly show neurological and psychiatric symptoms, which often 
include headache, vertigo, diplopia, vomiting, phrenitis, and irritation. A minority of 
patients exhibit symptoms of derangement, meningeal irritation, or even coma. Further 
examination typically reveals increased pressure in the cerebrospinal fluid and edema 
in the optic papilla. In these cases, encephaledema often co-occurs, as can be detected 
by encephalic CT or MRI examination.  
e. At the onset of HAPE, there is usually no fever, but some patients show low fever and 
intolerance to coldness.  
6.3 Diagnostic examination 
a. Hemogram: The leukocyte count is typically normal or mildly increased; about 40% 
patients have a count over 10000/mm3. The highest count recorded in our study was 
64000/mm3. The neutrophilic granulocyte count also increases mildly. If the leukocyte 
and neutrophilic granulocyte counts continue to rise, it usually indicates concurrent 
infection. 
b. X-rays: HAPE patients often show unilateral or bilateral flake-like or cloudy shadows 
centered at the porta pulmonis, mostly in the right lung. A minority of patients show 
large patchy or butterfly/batwing shadows. The apex regions of the lung are usually 
clear. At early stages, there is only thickening of the lung markings, also called 
pulmonary interstitial edema. 
c. Electrocardiography: Manifestations of HAPE on the electrocardiogram include nodal 
tachycardia, right axis deviation, right bundle branch blockage, sharply tented P waves 
or P pulmonale, T wave inversion, and ST segment depression. 
d. Blood gas: HAPE patients show substantial decreases in levels of PaO2 and SaO2, which 
are not only lower than those of healthy controls but also significantly lower than those 
of mild AMS patients.  
e. Pulmonary function: HAPE mainly features decreases in the expiratory flow rate or 
diffusion capacity. 
f. Hemodynamics: The pulmonary arterial pressure and resistance to the pulmonary 
artery are significantly increased. Left atrial pressure remains normal.  The pulmonary 
capillary wedge pressure and cardiac index remain normal or decrease slightly. 
7. Clinical classification 
Using clinical signs and symptoms and the results of diagnostic examination, HAPE can be 
classified into three types: mild, moderate, and severe. 
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1. Mild HAPE: Characterized by mild dyspnea, coughing, coughing out small amounts of 
spumous phlegm, focal moist rales at the base of one or both lungs, respiratory rate of 
20-30 breaths/minute, pulse rate under 100 beats/minute, bilateral thickening of lung 
markings, or cloudy spots at the base of the lungs visible on sternal X-ray. 
2. Moderate HAPE: Characterized by substantial dyspnea, chest pain, chest tightening, 
coughing out large amounts of white or pink spumous phlegm, moist rales at the base 
of both lungs spreading over other pulmonary regions, respiratory rate of 30-40 
breaths/minute, pulse rate of 110-120 beats/minute, bilateral thickening of lung 
markings, and flake-like or cloudy shadows at the base of the lungs visible on sternal X-
ray. 
3. Severe HAPE: Characterized by polypnea, panic, inability to lie flat, coughing out large 
amounts of pink spumous phlegm, severe cough, considerable blowing systolic 
murmur upon examination of the apex region of the heart or pulmonary valve area, 
moist rales sounding like boiling water in all pulmonary regions, bilaterally 
symmetrical cloudy shadows centered at the porta pulmonis or bilaterally symmetrical 
butterfly/batwing shadows visible on sternal X-ray, heart enlargement, clear 
protruding of the pulmonary trunk, and in some cases signs of heart failure including 
jugular vein distention, hepatomegaly, and edema in both lower extremities. 
8. Diagnosis and differential diagnosis 
8.1 Diagnosis and diagnostic criteria 
1. Clinical diagnostic criteria 
In China, the clinical diagnosis of HAPE is mostly based on the clinical diagnostic criteria 
recommended in 1995 by the Chinese Medical Association’s third national medicine 
academic seminar. These criteria have been approved by the International Society for 
Mountain Medicine. The criteria include the following: 
a. Upon recent exposure to high altitudes (usually considered to be 3,000 meters or more 
above sea level), the subject experiences dyspnea at rest, chest stress and tightening, 
cough, coughing out white or pink spumous phlegm, malaise, or decreased activity. 
b. There are unilateral or bilateral moist rales or wheezing sounds in the pulmonary field, 
central cyanosis, tachypnea, and tachycardia. 
c. X-ray shows unilateral or bilateral flake-like or cloudy infiltrated shadows centered at 
the porta pulmonis, often scattered and irregularly distributed but sometimes fused 
into a large patch. The podoid is normal in most cases, but sometimes signs of 
pulmonary hypertension and right heart enlargement can also be observed. 
d. Other cardiac and pulmonary diseases, such as myocardial infarction and heart failure are 
excluded by clinical and electrocardiographic examinations. Pneumonia is also excluded. 
e. Symptoms quickly improve after bed rest, oxygen inhalation treatment, or descending 
to a lower altitude, and signs shown by X-ray disappear within a short period of time. 
2. Criteria for early diagnosis 
As we gain a deeper knowledge of HAPE and accordingly improve both protective and 
therapeutic measures, clinically typical HAPE cases have become rare. If we continue to 
refer to the previous diagnostic criteria, it will be difficult to identify HAPE patients. For this 
reason, we carried out a study funded by the National Sci-Tech Support Plan and proposed 
the following as the criteria for early diagnosis of HAPE: 
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a. Upon recent exposure to high altitudes (usually considered to be 3,000 meters or more 
above sea level), the at-rest subject experiences palpitations, chest tightening, dyspnea, 
and coughing with or without small amounts of white spumous phlegm. 
b. There is local, unilateral or bilateral coarse breathing with or without focal moist rales. 
There is also central cyanosis, tachycardia (100 beats/minute), and tachypnea (24 
breaths/minute). 
c. Early routine X-ray examination shows a decrease in transmittance of the lungs, blurred 
or increased lung markings, and the presence of ground-glass opacity or small patchy 
shadows in the lung. CT scan shows increased number and thickening of lung 
markings, ground-glass opacity, nodular shadows, scattered or isolated alveolar edema 
on terminal bronchioles, and fine reticular shadows. 
d. Routine blood examination shows increases in the leukocyte count and the proportion 
of neutrophilic granulocytes. 
e. Arterial blood gas examination shows persistent hypoxemia accompanied by mild 
respiratory alkalosis. 
f. Electrocardiographic examination shows nodal tachycardia, clockwise rotation, sharply 
tented P waves, and so on. 
g. Ultrasonic cardiogram shows early, prominent, persistent pulmonary hypertension. 
h. All symptoms quickly improve after treatment such as bed rest, oxygen inhalation, 
decreasing pulmonary arterial pressure, and diuresis. 
It should be noted that criteria a-c must be met first. Conditions in d-h are then evaluated. 
The criteria are then combined collectively to produce an accurate early diagnosis. In clinical 
practice under aforementioned criteria, if we also refer to the severities of the condition and 
of the signs, the features and sizes of the shadows on the chest film, make proper diagnoses, 
and give prompt, effective, on-site treatment, it is completely possible that we will be able to 
keep early-stage HAPE under control. 
8.2 Differential diagnosis 
1. Adult respiratory distress syndrome 
a. Differences in the cause of disease: The fundamental cause of HAPE is oxygen shortage 
at high altitudes and low pressure leading to disturbed pulmonary circulation and body 
fluid maldistribution, of which oxygen shortage is the cause. ARDS is the secondary 
lesion of the lung tissues directly or indirectly caused by trauma or severe infection, in 
which oxygen shortage is the consequence. 
b. Differences in pathological changes: Both show high levels of permeability edema. 
However, HAPE features short duration, fibrosis of the interstitial tissues and alveolar 
walls, thickening of the interstitium, only mild hyperplasia in the epithelial cells of 
alveolar walls, and a full recovery without sequelae. ARDS may evolve into subacute 
and chronic conditions, such as alveolar wall fibrosis. Chronic patients may exhibit 
pathological changes in general bronchopneumonia, which can eventually lead to 
prominent fibrosis of the interstitium and the alveoli and the pathological changes of 
emphysema. 
c. Differences in reaction to oxygen inhalation: After treatments such as oxygen inhalation 
and measures that decrease pulmonary arterial pressure, most HAPE patients can 
quickly improve and recover in 2-7 days. Only in rare cases will patients die, usually 
due to a long delay before treatment, extreme severity of the condition, or complication 
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by adult respiratory distress syndrome. ARDS usually features more severity and a 
longer duration, often with hemosputum or hemorrhagic sputum and unilateral or 
focal tubular sound with few moist rales. Oxygen inhalation, even high-pressure 
oxygen inhalation and assisted respiration, is often not effective. The fatality rate is 
relatively high, usually between 40% and 70%. 
d. Differences in X-ray manifestations: HAPE often shows flake-like or cloudy shadows 
spreading outward from the porta pulmonis, mostly scattered at the middle and lower 
fields and rarely fused into large patch. The X-ray film of ARDS patients typically 
shows patchy shadow at the edges of the lungs, in server cases fused into a large patch. 
At the terminal stage, “white lung” is manifested, and the pulmonary shadows 
gradually disappear. 
2. High altitude pneumonia 
High altitude pneumonia and upper respiratory tract infection can trigger HAPE, and 
HAPE tends to be complicated by high altitude pneumonia. Therefore, we should carefully 
differentiate the two in both diagnosis and treatment. 
a. Differences in cause: HAPE is caused by hypoxia under low-oxygen, low-pressure 
conditions at high altitudes. High altitude pneumonia is pulmonary inflammation 
caused by bacteria, viruses, allergies, or inhalation of hazardous substances such as 
kerosene or gasoline. 
b. Differences in clinical manifestation: Both show increases in body temperature and 
hemogram. However, high altitude pneumonia usually has a rapid onset with chills 
and high fever. Body temperature reaches 39-40oC within hours and continues to rise, 
causing enecia. Both the leukocyte and the neutrophilic granulocyte counts increase 
significantly, reaching up to 20-30×109/L. Mostly neutrophilic granulocytes can reach 
more than 80%. There is also a left shift of nuclei, observable toxic granulations, and 
vacuoles in the cytoplasts. In comparison, HAPE patients usually do not have fever 
higher than 38.5oC, and their leukocyte and neutrophilic granulocyte counts only 
increase slightly. 
c. Differences in clinical signs: HAPE patients cough typical spumous hemosputum or 
pink spumous phlegm, which can gush out from mouth and nose when large amounts 
are present. High altitude pneumonia patients first cough mucus and then purulent or 
rusty sputum. 
d. Differences in X-ray manifestation: HAPE often shows either intense shadows with 
different densities, shapes, and sizes, or spotty, flake-like, cloudy shadows. Lesion 
margins of HAPE were blurred and not constrained by the interlobar fissures. The 
above signs are widely scattered in both lungs. High altitude pneumonia shows 
increased numbers of lung markings and decreased transmittance of the lung fields at 
early stages. Later spotty, flake-like shadows of different sizes can be observed, 
sometimes fused into patchy shadow, but usually limited to one pulmonary lobe or one 
pulmonary segment. 
9. Complications 
9.1 High Altitude Cerebral Edema 
High altitude cerebral edema (HACE) is a common complication of HAPE, as verified by 
clinical examinations, lab examinations, and autopsies. Because patients may have one or 
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both of these two diseases, we should take great caution in diagnosis and treatment. HAPE 
patients often show signs and symptoms such as headache, vomiting, hypersomnia, and 
coma, which relate to increased intracranial pressure and cerebral edema. Fundus 
examination sometimes shows papilledema and fundus hemorrhage, and lumbar puncture 
often shows increased cerebrospinal fluid pressure. Such cases merit special attention 
during diagnosis and treatment. 
Shortly after rapid exposure to a high altitude environment, blood within the body is 
redistributed via neural, fluid regulation. The vasomotion of the blood vessels in some 
organs undergo prominent changes resulting in large amounts blood moving to important 
organs, such as the lung, heart, and brain, ensuring their oxygen supply and normal 
function. However, if the blood flow volume, rate, and pressure in these organs become too 
high, disruption to microcirculation may occur. In particular, in the lung and brain, where 
low-pressure space is normally present, it can easily cause fluid to leak out into neighboring 
tissues, leading to edema. HAPE and HACE share some common pathogenesis, for the most 
part in the pathological changes in hemodynamics. HACE and HAPE may occur separately 
or jointly, sometimes in succession. Severe HAPE and large amounts of extravasation from 
the alveoli seriously impair oxygen uptake from the external environment, aggravating 
hypoxemia, which promotes the hemangiectasis of the cerebral blood-vessels via 
neuroendocrine regulation induced by severe hypoxia of the brain tissue. The resulting 
increase in cerebral blood flow and blood volume then further aggravates cerebral edema. 
However, HACE escalates the extravasation of pulmonary tissue and worsens HAPE via 
neural, fluid regulation. When HACE extends to the respiratory and cardiovascular centers 
of the medulla oblongata, respiration is inhibited and blood pressure drops, in severe cases 
leading to cerebral hernia, which can cause respiratory circulation failure or even sudden 
cardiac arrest，resulting in vicious circle. This is an important cause of death among 
patients with HAPE complicated by cerebral edema.  
9.2 Cerebral infarction 
Cerebral infarction is another common complication of HAPE, possibly induced by the 
following: 1) Acute erythrocytosis occurs due to excessive erythropoiesis triggered when the 
body is exposed to altitudes above a certain elevation. The compensatory erythrocytosis in 
the plasma leads to a significant increase in blood viscosity. Blood flow rate decreases and 
blood cells cluster together, resulting in increased contact between the platelets and the 
blood vessel walls, rendering the blood more likely to coagulate. 2) Wade et al. proposed 
that disturbances in cerebral circulation might play a major role in generating cerebral 
thrombosis. HAPE complicated with HACE is an important cause of disturbances in 
cerebral microcirculation, which slows down the blood flow and increases the blood 
viscosity of the patient, leading to cerebral thrombosis. 3) At high altitudes, the generation 
of blood coagulation factor in the plasma increases, creating a hypercoagulative condition. 
The blood of High altitude polycythemia (HAPC) patients is already in a hypercoagulative 
state, and second hyperfibrinolysis can easily occur. 4) HAPE patients have severe 
hypoxemia, which may result in damage to blood vessel endothelial cells. The above 
changes caused severe damage to the pulmonary capillary endothelial cells of HAPE 
patients, boosting platelet adhesion and activating the blood coagulation system, finally 
leading to cerebral thrombosis.   
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9.3 Multiple Organ Dysfunction Syndrome 
Patients with HAPE complicated by cerebral edema are prone to multiple organ dysfunction 
syndrome (MODS). Patients show symptoms including headache, chest tightness, shortness 
of breath, nausea, aggravated vomiting, and abnormal psychological behavior. Auscultation 
can reveal aggravated pulmonary rales; fundus  examination may show spotting or patchy 
bleeding in the retina and papilledema; there is gastrointestinal hemorrhage or fecal occult 
blood, hematuria, or proteinuria; chest X ray of most patients show enlarged hilar shadows, 
unilateral or bilateral cloudy shadows of uniform density in the lung field, in some cases 
fused into large, dense, patchy unilateral or bilateral shadows of uniform density; 
encephalic CT reveals decreased brain parenchymal density, narrowed bilateral cerebral 
ventricles, and the shallower, narrower sulci; laboratory examination will reveal increased 
leukocyte counts, often above 13.0×109/L, increased bleeding and clotting time, increased 
fibrinolytic activity, and increases in thromboxane B2, vWF, fibrinogen, tissue-type 
plasminogen activator and inhibitor in the plasma, increased levels of D-dimers, increased 
levels of alpha-granular membrane protein, significantly decreased levels of 6-keto-PGF1a 
and antithrombin III, and severe dysfunction of the coagulation and fibrolysis systems. 
AMS complicated by MODS has been underemphasized and the diagnostic yield has been 
low. Our investigation shows that 2.5% of AMS cases are complicated by MODS, which is 
considerable. We need to improve early diagnosis and early detection because early 
treatment is crucial in reducing the fatality rate of AMS complicated by MODS. 
10. Prevention and treatment 
10.1 Prevention 
1. Protection of susceptible populations from exposure to high altitudes 
Physical examinations, especially inspections of cardiac and pulmonary functions, should be 
performed on individuals who are about to travel to high altitude areas. Those with heart 
and/or lung ailments should be advised against exposure to high altitudes. 
2. Prevention of respiratory tract infection 
Individuals with respiratory tract infections are more susceptible to HAPE at high altitudes. 
Those who catch upper respiratory tract infections before planned trips to high altitude 
areas should first seek treatment and only make the trip after full recovery. Prior to high 
altitude exposure, one should perform cold resistance exercises. After arrival, one should 
take active measures to keep warm and prevent respiratory tract infection. 
3. Acclimatization to hypoxia 
Prior to high altitude exposure, one should receive hypoxic training using masks or hypoxic 
respirators to increase the body’s tolerance to hypoxia so as to promote high altitude 
acclimatization.  
When possible, one should ascend to higher altitudes gradually and multisteply rather than 
rapidly ascend to higher altitudes to avoid body damage. Before traveling to high altitude 
regions, individuals should familiarize themselves with the climate characteristics and 
geological environment of the area and familiarize themselves with preventative treatments 
for high altitude diseases. 
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4. Reduction and control of activity level 
During the first week of high-altitude exposure, one should take proper rest, reduce or 
avoid intense physical activity, avoid fatigue, and minimize oxygen consumption. Normal 
physical activity should be resumed only after the body is acclimatized to the hypoxic 
environment. 
5. Administration of prophylactic medicine 
a. Chinese traditional medicine  
There are four courses of Chinese traditional medicines that may serve to prevent 
HAPE: 
Compound codonopsis tablets: Take orally. Start 3 days before hypoxia exposure, 3-5 
tablets/dose, 3 doses each day. Continue for 5-7 days after hypoxia exposure. 
Ginseng and astragalus pollen tablets: Take orally. Start 3 days before high altitude 
exposure, 5 tablets/dose, 3 doses/day. Continue for 5-7 days after high altitude 
exposure. 
Rhodiola rosea oral solution: Take orally. Start 3 days before high altitude exposure, 10 
ml/dose, 3 doses/day. Continue for 5-7 days after high altitude exposure. 
Compound rhodiola capsules: Take orally. Start 3 days before high altitude exposure, 2 
capsules/dose, 3 doses/day, continue for 5-7 days after high altitude exposure. 
b. Glucocorticoid preparations 
Dexamethasone: Take orally. Start 1 day before high altitude exposure, 5 mg/dose, 3 
doses/day. Continue for 2 days after high altitude exposure. 
c. Carbonic anhydrase inhibitors 
Nephramid (a.k.a. acetazolamide): Take orally. Start 1 day before high altitude 
exposure, 250 mg/dose, 3 doses/day. Take for 2-3 days. 
Methazolamide (a.k.a. Ni Mu Ke Si): Take orally. Start 1 day before high altitude 
exposure, 25-50 mg/dose, 3 doses/day. Take for 2-3 days. 
d. Calcium antagonists 
Nifedipine: Take orally. Start 1 day before high altitude exposure, 10 mg/dose, 2 
doses/day or sublingual administration 10 mg/dose, 3 doses/day. Take for 1-3 days. 
e. Beta2- receptor stimulants 
Salbutamol: Inhale. Start 1 day before high altitude exposure, 125 g/dose, 2 
doses/day. Continue for 2-3 days after high altitude exposure. 
f. Phosphodiesterase inhibitors  
Sildenafil: Take orally. Start 1 day before high altitude exposure, 50 mg/dose, 3 
doses/day. Continue for 2-3 days after high altitude exposure. 
Tadalafil: Take orally. Start 1 day before high altitude exposure, 10 mg/dose, 1 
dose/day. Continue for 2-3 days after high altitude exposure. 
10.2 Treatment 
Accurate, effective early-stage treatment usually quickly improves symptoms. Therefore, 
early diagnosis and timely treatment are crucial to controlling the course of the disease and 
prognosis. 
1. Oxygen inhalation or hyperbaric oxygen therapy 
Oxygen inhalation can substantially decrease pulmonary arterial pressure in HAPE patients 
and quickly alleviate hypoxia and the series of clinical symptoms that it causes. HAPE 
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patients should in general use continuous administration of low-flow oxygen (4-6 
L/minute). For patients with severe hypoxia, high-flow continuous oxygen may be 
administrated (8-10 L/minute) but for no longer than 24 hours in order to avoid oxygen 
toxicity. If the symptoms include excessive spumous phlegm, an appropriate amount of 
alcohol may be added to the oxygen humidifying containers for froth suppression.  
Hyperbaric oxygen treatment can temporarily remove hypoxia for HAPE patients. Most 
patients show symptom improvement after 1-2 treatments and achieve recovery after 2-3 
treatments. However, for a minority of patients, HAPE signs and symptoms worsen after 
departure from the hyperbaric oxygen chamber, which can be associated with disease 
severity variance and individual difference. Therefore, when treating HAPE patients with 
hyperbaric oxygen therapy, caution should be taken to acknowledge individual variability 
and monitor the severity of the condition. 
2. Nitric oxide inhalation 
Inhalation of low-concentration nitric oxide can quickly, selectively alleviate the pulmonary 
hypertension caused by hypoxia. The inhalation method is as follows: Mix 10 ppm nitric 
oxide with pure air and inhale through a nasogastric feeding tube at 3-5 L/minute, 30-60 
minutes/treatment and 2-3 treatments/day. Patients with mild or moderate HAPE typically 
recover after 2-3 days. For severe HAPE patients, the duration and daily frequency of the 
inhalation treatments should be increased accordingly. 
Inhaled nitric oxide can be oxidized into NO2- and NO3- in high-oxygen environments and 
can accumulate in the blood, which will damage the blood cells. For this reason, when 
treating HAPE patients with nitric oxide, simultaneous inhalation of high concentration 
oxygen should be avoided. Animal studies have shown that the effects of inhaling 
concentrations of nitric oxide ranging from 5-80 ppm on decreasing pulmonary arterial 
pressure are statistically the same.  
3. Aminophylline 
Aminophylline is the drug of choice for standard HAPE treatment. It can quickly diminish 
pulmonary arterial and vena cava pressure and decrease right atrial venous return volume. 
It can also be cardiotonic, diuretic and a smooth muscle relaxant and can reduce resistance 
in the systemic circulation, improving the heart function. 
Regular dose: 0.25g diluted to 20ml 10-50% glucose, intravenously injected at an even speed. 
It can be repeated after 4-6 hours. For mild HAPE patients, administer 2 times/day. For 
severe patients, upgrade to 0.5g/administration, and increase the frequency of 
administration according to the severity. 
4. Anticholinergic agents 
Atropine and anisodamine can treat pulmonary vasospasms. They also decrease resistance 
in the pulmonary blood vessels, improve pulmonary microcirculation, keep pulmonary 
blood flow unimpeded, and prevent blood clotting and pulmonary thrombosis inside the 
blood vessels. 
Regular dose: Atropine 2-5 mg/0.5hour. Anisodamine (654-2) 20-40 mg/0.5 hour, 
intravenous drip. 
5. Dexamethasone 
Dexamethasone can be used in both treating and preventing HAPE. Regular dose: 10 mg, IV 
injection, 2 times/day for no more than 3 days. For patients with comorbid conditions such 
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as epilepsy, peptic ulcer, high blood pressure, or diabetes mellitus, dexamethasone should 
be taken with caution or contraindicated. 
6. Diuretics 
Nicorol: 10 mg IV injection, 1 dose/day; Nephramid: Take orally.250 mg/dose, 3 
doses/day; Drugs that alleviate pulmonary hypertension: nifedipine: 10-20 mg/dose orally 
or sublingually, 2 doses/day. Sodium nitroprusside: IV drip, 10-20 mg/dose. 
7. Cardiotonics 
Cedilanid: IV injection, 0.4-0.8 mg. Strophanthin K: IV injection, 0.125-0.5 mg. 
8. Sedatives 
Morphine hydrochloride: 5-10 mg, subcutaneous injection. In severe cases, dilute 5 mg to 20 ml 
10% glucose and administer IV injection. For some patients with anxiety symptoms, Valium 
may be used with caution, but its inhibitory effects on breathing should be monitored. 
9. Antibiotics 
HAPE is very likely to be complicated by pulmonary infection. When the two diseases co-
occur, each aggravates the other and the situation becomes difficult to control. In treating 
HAPE, broad-spectrum antibiotics are usually used to prevent and treat infection. Patients 
with mild symptoms should take broad-spectrum antibiotics (e.g. amoxicillin, norfloxacin, 
trimethoprim and sulphame-thoxazole etc.) orally for anti-infection purposes, and control 
the intake of sodium chloride to avoid worsening the HAPE. The commonly used antibiotics 
include the following: 
a. Amoxicillin: Take orally, 1g/dose, 3 doses/day. 
b. Norfloxacin: Take orally, 0.2g/dose, 3 doses/day. 
c. Trimethoprim and sulphame-thoxazole: Take orally, 1-2 tablets/dose, 2 doses/day, take 
orally. 
d. Levofloxacin: Take orally, 0.1-0.2 g/dose, 2 doses/day. 
e. Penicillin (still the first choice): 4,800,000-6,400,000 units diluted in 250-500 ml glucose 
or saline, IV drip, 1-2 times/day. Contraindicated in patients clinically significant  
allergy to penicillin. 
f. Ampicillin sodium/sulbactam sodium: For mild infections, 1.5g/day in 2-3 IM 
injections. For moderate infections, 4-9g/day in 3-4 IM injections. For severe infections 
9-12g/day in 2-3 IV drips.  
g. Cefamezin: 2g/dose, 3 doses/day, IV drip. 
h. Cefradine: 100-150 mg/kg/day, IV drip. 
i. Lincomycin hydrochloride: 0.6g/dose, 1-2 doses/day, IV drip. 
j. Ciprofloxacin Lactate: 0.2g/dose, 2 doses/day, IV drip. 
10. Decent to lower altitude 
When possible, patients should be quickly transferred to lower altitudes (below 3,000 
meters) for further treatment. After leaving the hypoxic environment, the elevated 
pulmonary arterial pressure can quickly return to normal levels and the series of symptoms 
caused by hypoxia quickly disappear. However, descent treatment is only applicable in less 
remote areas within a relatively short amount of time. In remote mountain areas where 
transportation conditions are extremely poor and continuous oxygen supplies cannot be 
guaranteed in transit, it is for the best to administer on-site treatment.  
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When transferring patients to lower altitudes, the following should be noted: 1) 
Transportation utilities: fast, stable transportation utilities are preferable, e.g. helicopter, 
truck, heavy medical vehicle, small ambulance. 2) Accompanying crew: there should be one 
doctor and one nurse, or at least one medical professional who can perform effective 
treatment through the transfer. 3) The patient in should assume a semireclining position 
during descent to keep the airway clear. 4) Patients with high altitude coma should assume 
a semireclining position. Head movement and vehicle pitching should be minimized to 
prevent cerebral hernia. 5) The driver should proceed slowly when road conditions are 
rough so that the patient’s position can remain relatively stable. 6) The accompanying crew 
should read and record vital signs and give effective treatment when needed. 7) If a patient 
passes away, the time and order of vital sign loss should be recorded and body position 
should respectfully be kept unchanged. 
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